
## What is claimed is:

- 1. A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding Interferon gamma receptor 2, wherein said compound specifically hybridizes with and inhibits the expression of Interferon gamma receptor 2.
- 2. The compound of claim 1 which is an antisense oligonucleotide.
- 3. The compound of claim 2 wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO: 18, 19, 20, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 38, 39, 40, 41, 42, 45, 47, 48, 49, 51, 52, 55, 56, 57, 59, 61, 62, 63, 65, 66, 68, 69, 70, 71, 72, 73, 74, 76 or 86.
- 4. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.
- 5. The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothicate linkage.
- 6. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.
- 7. The compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.
- 8. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.
- 9. The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.
- 10. The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.
- 11. A compound 8 to 50 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of an active site on a nucleic acid molecule encoding Interferon gamma receptor 2.
- 12. A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.
  - 13. The composition of claim 12 further comprising a



- 14. The composition of claim 12 wherein the compound is an antisense oligonucleotide.
- 15. A method of inhibiting the expression of Interferon gamma receptor 2 in cells or tissues comprising contacting said cells or tissues with the compound of claim 1 so that expression of Interferon gamma receptor 2 is inhibited.
- 16. A method of treating an animal having a disease or condition associated with Interferon gamma receptor 2 comprising administering to said animal a therapeutically or prophylactically effective amount of the compound of claim 1 so that expression of Interferon gamma receptor 2 is inhibited.
- 17. The method of claim 16 wherein the disease or condition is an autoimmune disorder.
- 18. The method of claim 17 wherein the autoimmune disorder is autoimmune thyroiditis, diabetes, multiple sclerosis, autoimmune arthritis, autoimmune insulinitis or Crohn's disease.
- 19. The method of claim 16 wherein the disease or condition is cancer.
- 20. The method of claim 16 wherein the disease or condition is caused by aberrant apoptosis.